Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

National Glaucoma Research
Completed Award

Dr. Peter Koulen

Peter Koulen, Ph.D.

University of Missouri at Kansas City
Kansas City, MO

Title: Protection of ONH astrocytes and structure in glaucoma
Non-Technical Title: Protection of the most damaged eye structure in glaucoma

Duration: April 1, 2010 - September 30, 2012
Award Type: Standard
Award Amount: $100,000

Summary:

Degeneration or acute damage of the retina due to glaucoma related disease processes is a major cause of visual loss and blindness in the United States and worldwide. As glaucoma affects significant and increasing portions of the U.S. population including minorities affected by disparities in health care delivery, determining causes, mechanisms of action and subsequently potential treatment strategies will contribute to improving health care, health and performance requiring visual tasks. This study uses a novel mechanism underlying a self-defense mechanism of the retina to protect a critical structure of the retina, the optic nerve head, in order to develop new treatment strategies that have the potential to be complementary in nature to current strategies aimed at neuroprotection or aimed at lowering intraocular pressure.

Details:

Degeneration or acute damage of the retina due to glaucoma related disease processes is a major cause of visual loss and blindness in the United States and worldwide. As glaucoma affects significant and increasing portions of the U.S. population including minorities affected by disparities in health care delivery, determining causes, mechanisms of action and subsequently potential treatment strategies will contribute to improving health care, health and performance requiring visual tasks. This study uses a novel mechanism underlying a self-defense mechanism of the retina to protect a critical structure of the retina, the optic nerve head, in order to develop new treatment strategies that have the potential to be complementary in nature to current strategies aimed at neuroprotection or aimed at lowering intraocular pressure.

Our approach is characterized by two novel aspects for glaucoma research and glaucoma therapy development:

  1. Identification and use of a novel drug target in mitochondria of optic nerve head astrocytes (ONHA)
  2. Targeting ONHA activation, dysfunction and degeneration along with a pathological re-structuring of the ONH extracellular matrix in a novel intervention approach that has the potential to be complementary in nature to current strategies aimed at neuroprotection or aimed at lowering intraocular pressure.

Publications:

Burroughs S. L., Kaja S. and Koulen P. (2011) Quantification of deficits in spatial visual function of mouse models for glaucoma. Invest. Ophthal. & Vis. Sci., 2011 Jun 1;52(6):3654-9. PubMed Icon Google Scholar Icon

Progress Updates:

Dr. Koulen’s team accomplished the following goals of this research project: 1) identify a novel drug target in mitochondria of the optic nerve head (ONH) astrocytes (ONHA; essentially, the supporting cells of the optic nerve); and 2) use a novel intervention approach to target this identified protein so as to prevent ONHA activation, dysfunction, and degeneration, and also prevent the pathological re-structuring of the ONH extracellular matrix (i.e. the cell’s support scaffolding).

The team accomplished their goals by doing the following experiments:

  • Studied ONHAs as the main contributors to disease-related changes in the structure and function of the optic nerve head (the eye structure most affected by glaucoma)
  • Measured the molecular properties of the novel drug target in mitochondria of  ONHA
  • Measured the effect of chemically-mediated control of this novel drug target to restore or prevent glaucoma-related activation of ONHA
  • Generated a potentially novel strategy to protect the function of the eye affected by glaucoma, that would be complementary to existing strategies that lower intraocular pressure.

Dr. Koulen’s team published a portion of this work in the highly ranked, peer-reviewed journal IOVS; in particular, they reported a functional characterization of a new research model system that could enable the glaucoma research community to develop novel anti-glaucoma drugs.

::

]]